1. Home
  2. ILAG vs AKTX Comparison

ILAG vs AKTX Comparison

Compare ILAG & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intelligent Living Application Group Inc.

ILAG

Intelligent Living Application Group Inc.

HOLD

Current Price

$2.50

Market Cap

7.9M

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.25

Market Cap

9.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ILAG
AKTX
Founded
1981
N/A
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
9.1M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
ILAG
AKTX
Price
$2.50
$0.25
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$2.53
AVG Volume (30 Days)
75.6K
306.2K
Earning Date
12-22-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,338,785.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.04
$0.22
52 Week High
$9.80
$1.73

Technical Indicators

Market Signals
Indicator
ILAG
AKTX
Relative Strength Index (RSI) 45.31 44.92
Support Level $2.40 $0.23
Resistance Level $2.74 $0.27
Average True Range (ATR) 0.62 0.02
MACD -0.17 0.00
Stochastic Oscillator 12.62 48.25

Price Performance

Historical Comparison
ILAG
AKTX

About ILAG Intelligent Living Application Group Inc.

Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: